A Phase I clinical study of a subtype selective NMDA receptor negative allosteric modulator (NAM) for the treatment of treatment-resistant depression.
Phase of Trial: Phase I
Latest Information Update: 26 Oct 2017
At a glance
- Drugs NMDA receptor modulators (Primary)
- Indications Depressive disorders
- Focus Adverse reactions
- Sponsors Novartis
- 26 Oct 2017 New trial record
- 17 Oct 2017 According to a Cadent Therapeutics media release, Cadent Therapeutics has earned a milestone payment from Novartis for the initiation of this Phase 1 clinical study.